WVE-006

Wave Life Sciences achieves first-ever RNA editing results in humans for alpha-1 antitrypsin deficiency, demonstrating therapeutic protein level increases with a single dose treatment.

Wave Life Sciences demonstrates groundbreaking success with WVE-006, the first RNA-editing therapy tested in humans for alpha-1 antitrypsin deficiency, showing 60% increase in functional enzyme levels.

Wave Life Sciences is set to initiate dosing for WVE-007 in its Phase 1 INLIGHT trial for obesity in Q1 2025, with proof-of-concept data expected later in the year.

Korro Bio has received approval to begin a Phase I/IIa trial in Australia for KRRO-110, an RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

Wave Life Sciences reported the first-ever RNA editing in humans with WVE-006 for alpha-1 antitrypsin deficiency (AATD), showing increased wild-type AAT protein levels.